Briz et al
1 described a method to detect maternal cell contamination of cord blood. They used PCR amplification of genomic hypervariable regions followed by run on agarose gels stained with ethidium bromide and visualised under UV transillumination. In our opinion, the method used by Briz et al, although simple and inexpensive, has a low sensitivity to identify maternal cells in cord blood samples. The sensitivity reported was between 0.5 and 1% with a contamination incidence of 1.25% (one contaminated of 80 cord blood samples). Sociè et al 2 reported the same sensitivity levels using minisatellite PCR amplification followed by Southern blotting and radioactive detection. In this way the authors identified one contaminated cord blood sample out of 47. Later on, the same group reported a more sensitive technique to identify maternal DNA contamination. 3 They described a PCR amplification of the polymorphic TPO sequence followed by Southern blotting and radioactive detection with a sensitivity of 0.01%.
A sensitivity as high as this can also be obtained through techniques which do not need radioactivity. 4 In our experience, we achieved a sensitivity of 0.04% with a contamination incidence of 18% (11 contaminated of 60 cord blood samples). 5 We used a PCR amplification of genomic hypervariable regions, followed by chemiluminescent detection.
Many other papers dealing with this subject [2] [3] [4] [5] [6] [7] [8] have been published with a variable contamination incidence depending on the technique used.
In our opinion it would be more important to establish at what level the maternal cell contamination may exert a clinically relevant effect, if the maternal contamination is due to metabolically active cells, which kind of cells are involved, what is the number of maternal cells acceptable in a cord blood transplantation and what is the possible correlation between GVHD and maternal contamination. We underline the importance of correlating the contamination data with clinical results. This could be achieved with retrospective studies on cord blood transplanted patients who experienced GVHD and with an analysis of the maternal contamination entity using a standard method with a defined sensitivity. Otherwise, the conclusions drawn on the contamination rate can be misleading.
Anaphylactoid reaction to granulocyte colonystimulating factor used in mobilization of peripheral blood stem cell
With wider use of the hematopoietic growth factors in both allogeneic and autologous stem cell transplantation, several unusual complications such as splenic rupture and anaphyl
We suggest that a workshop should be set up to analyse the problem of maternal cell contamination in cord blood samples and to establish an appropriate standard method to detect maternal contamination.
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